Growth of GA lesions slowed by avacincaptad pegol in clinical trial
February 11th 2022Angiogenesis
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared to sham treatment.
Subretinal implant found to be safe, well-tolerated in patients with advanced dry AMD
February 11th 2022Angiogenesis
This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.
Connexin-43 blockers show promise for treatment of diabetic retinopathy, AMD
February 11th 2022Angiogenesis
Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
Port delivery system efficiently delivers drugs to retina in patients with wet AMD, study reports
November 15th 2021AAO
In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Mark Wieland, MD, noted that the Port Delivery System with ranibizumab provides drug delivery over an extended period.
Ocular surface tumors, though rare, often prove deadly
November 13th 2021AAO
In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall, BS, MS, pointed out that an epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.
Optic nerve pallor proves prevalent in ZIKA virus patients, study finds
November 13th 2021AAO
During a presentation at the American Academy of Ophthalmology 2021 annual meeting, Denise Freitas, MD, reported that the ocular findings in infants with congenital Zika virus syndrome were similar among the affected infants and occurred frequently. The most prevalent of the findings was optic nerve pallor.
Bimatoprost implant reduces IOP for 2 years or more, study finds
November 12th 2021AAO
Felipe Medeiros, MD, in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.
Increase in corneal haze after corneal crosslinking connected with mitomycin C
November 12th 2021AAO
Shady Awwad, MD, in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.